J9
Glucocorticoid resistance inhibitor
Product Specifications
Background
J9, in combination with dexamethasone inhibits cell growth in T-cell acute lymphoblastic leukemia (T-ALL) through the upregulation of the glucocorticoid receptor. Patients can develop glucocorticoid resistance rendering the treatment ineffective. J9 and its mechanism of action provides a useful strategy for overcoming the resistance. The EC50 of J9 in combination with dexamethasone is 28 uM. J9 alone was less toxic.
Product Name Alternative
4-cyclopropyl-5- (pyridin-4-yl) pyrimidin-2-amine
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cancer | Cell Signaling | Epigenetics and Nuclear Signaling
Purity
99.9%
Weight
0.01
Format
White Solid
Solubility
Soluble in CDCI3
Molecular Formula
C12H12N4
Molecular Weight
212.26
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Cantley A.M., et al. (2014) ACS Medicinal Chemistry Letters 5.7: 754-759.
More Discoveries
Explore Other Products
Browse additional items from our catalog
47954061 1.0 µg DNA
TRNAC9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details 
GTR15367420 1 Vial
Lentiviral human SLC4A9 sgRNA gene knockout kit - Lentiviral human SLC4A9 sgRNA gene knockout kit (100)
Sign In for Pricing
View Details 
MBS6415772-01 0.1 mL
ELL (Elongation Factor RNA Polymerase II, C19orf17, DKFZp434I1916, ELL1, MEN) (APC)
Sign In for Pricing
View Details